Telomerase and the search for the end of cancer

Trends in Molecular Medicine

Volumn 19, Issue 2, 2013, Pages 125-133

  Mocellin, Simone ^a   Pooley, Karen A ^b   Nitti, Donato ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cancer; Gene therapy; Immunotherapy; Small molecule inhibitors; Targeted therapy; Telomerase; Telomere; TERT

Indexed keywords

[2 (3 NAPHTHALENE 2 YL BUT 2 ENOYLAMINO)BENZOIC ACID]; BETA CATENIN; BEVACIZUMAB; BRACO 19; DOCETAXEL; ETOPOSIDE; FLUCYTOSINE; GEMCITABINE; IMETELSTAT; MESSENGER RNA; PACLITAXEL; PROTEIN BAX; QUARFLOXIN; SINGLE WALLED NANOTUBE; TELOMERASE; TELOMESTATIN; TERTOMOTIDE; TRANSCRIPTASE; TRASTUZUMAB; UNCLASSIFIED DRUG; WNT PROTEIN; ZD 2767P;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; BREAST METAS; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL AGING; CELL DEATH; CELL DIVISION; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CELLS; CUTANEOUS T CELL LYMPHOMA; DNA DAMAGE; DNA SEQUENCE; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG SAFETY; DRUG SOLUBILITY; EMBRYONIC STEM CELL; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; GENOMIC INSTABILITY; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INTERNAL RIBOSOME ENTRY SITE; LEUKAPHERESIS; LIVER CELL CARCINOMA; LYMPHOMA; MITOCHONDRIAL TARGETING SIGNAL; MOLECULAR BIOLOGY; MOLECULAR CLONING; MULTIPLE MYELOMA; NEOPLASM; NEUROENDOCRINE TUMOR; NON SMA; NON SMALL; NONHUMAN; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE; RNA SEQUENCE; SENESCENCE; SOLID TUMOR; SOMATIC CELL; TELOMERE; TELOMERE SHORTENING; TUMOR GROWTH;

ANIMALS; HUMANS; NEOPLASMS; TELOMERASE; TELOMERE;

EID: 84873170179     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.11.006     Document Type: Review

References (95)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Hayflick L., Moorhead P.S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 1961, 25:585-621.
3. Bodnar A.G., et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998, 279:349-352.
4. Moyzis R.K., et al. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:6622-6626.
5. Blackburn E.H. Switching and signaling at the telomere. Cell 2001, 106:661-673.
6. de Lange T. How telomeres solve the end-protection problem. Science 2009, 326:948-952.
7. Gilson E., Geli V. How telomeres are replicated. Nat. Rev. Mol. Cell Biol. 2007, 8:825-838.
8. Greider C.W., Blackburn E.H. A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature 1989, 337:331-337.
9. Martinez P., Blasco M.A. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat. Rev. Cancer 2011, 11:161-176.
10. Calado R.T., Young N.S. Telomere diseases. N. Engl. J. Med. 2009, 361:2353-2365.
11. Artandi S.E. Telomere shortening and cell fates in mouse models of neoplasia. Trends Mol. Med. 2002, 8:44-47.
12. Harley C.B. Telomerase and cancer therapeutics. Nat. Rev. Cancer 2008, 8:167-179.
13. Shay J.W., Wright W.E. Telomerase therapeutics for cancer: challenges and new directions. Nat. Rev. Drug Discov. 2006, 5:577-584.
14. Blasco M.A., et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997, 91:25-34.
15. Feldser D.M., Greider C.W. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 2007, 11:461-469.
16. Gonzalez-Suarez E., et al. Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nat. Genet. 2000, 26:114-117.
17. Gonzalez-Suarez E., et al. Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J. 2001, 20:2619-2630.
18. Artandi S.E., et al. Constitutive telomerase expression promotes mammary carcinomas in aging mice. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:8191-8196.
19. Kim N.W., et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015.
20. Blasco M.A., Hahn W.C. Evolving views of telomerase and cancer. Trends Cell Biol. 2003, 13:289-294.
21. Langford L.A., et al. Telomerase activity in ordinary meningiomas predicts poor outcome. Hum. Pathol. 1997, 28:416-420.
22. Clark G.M., et al. Telomerase activity and survival of patients with node-positive breast cancer. J. Natl. Cancer Inst. 1997, 89:1874-1881.
23. Mocellin S., et al. Telomerase reverse transcriptase locus polymorphisms and cancer risk: a field synopsis and meta-analysis. J. Natl. Cancer Inst. 2012, 104:840-854.
24. Hahn W.C., Meyerson M. Telomerase activation, cellular immortalization and cancer. Ann. Med. 2001, 33:123-129.
25. Trujillo K.A., et al. Breast field cancerization: isolation and comparison of telomerase-expressing cells in tumor and tumor adjacent, histologically normal breast tissue. Mol. Cancer Res. 2011, 9:1209-1221.
26. Shay J.W., Wright W.E. Telomeres and telomerase in normal and cancer stem cells. FEBS Lett. 2010, 584:3819-3825.
27. Kyo S., Inoue M. Complex regulatory mechanisms of telomerase activity in normal and cancer cells: how can we apply them for cancer therapy?. Oncogene 2002, 21:688-697.
28. Greider C.W. Telomerase activity, cell proliferation, and cancer. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:90-92.
29. Gertler R., et al. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J. Clin. Oncol. 2004, 22:1807-1814.
30. Kobitsu K., et al. Shortened telomere length and increased telomerase activity in hamster pancreatic duct adenocarcinomas and cell lines. Mol. Carcinog. 1997, 18:153-159.
31. Raynaud C.M., et al. DNA damage repair and telomere length in normal breast, preneoplastic lesions, and invasive cancer. Am. J. Clin. Oncol. 2010, 33:341-345.
32. Engelhardt M., et al. Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon, and sarcoma. Clin. Cancer Res. 1997, 3:1849-1857.
33. Pascolo E., et al. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J. Biol. Chem. 2002, 277:15566-15572.
34. Damm K., et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J. 2001, 20:6958-6968.
35. El-Daly H., et al. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood 2005, 105:1742-1749.
36. Li Q., et al. Searching drug-like anti-cancer compound(s) based on G-quadruplex ligands. Curr. Pharm. Des. 2012, 18:1973-1983.
37. Neidle S. Human telomeric G-quadruplex: the current status of telomeric G-quadruplexes as therapeutic targets in human cancer. FEBS J. 2010, 277:1118-1125.
38. De Cian A., et al. Reevaluation of telomerase inhibition by quadruplex ligands and their mechanisms of action. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:17347-17352.
39. Kim M.Y., et al. Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular G-quadruplex. J. Am. Chem. Soc. 2002, 124:2098-2099.
40. Gomez D., et al. The G-quadruplex ligand telomestatin inhibits POT1 binding to telomeric sequences in vitro and induces GFP-POT1 dissociation from telomeres in human cells. Cancer Res. 2006, 66:6908-6912.
41. Tauchi T., et al. Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways. Oncogene 2003, 22:5338-5347.
42. Burger A.M., et al. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. Cancer Res. 2005, 65:1489-1496.
43. Miyazaki T., et al. Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb. Clin. Cancer Res. 2012, 18:1268-1280.
44. Taetz S., et al. Biopharmaceutical characterization of the telomerase inhibitor BRACO19. Pharm. Res. 2006, 23:1031-1037.
45. Phatak P., et al. Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell targeting mechanism. Br. J. Cancer 2007, 96:1223-1233.
46. Drygin D., et al. Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. Cancer Res. 2009, 69:7653-7661.
47. Mocellin S., et al. Part I: Vaccines for solid tumours. Lancet Oncol. 2004, 5:681-689.
48. Klebanoff C.A., et al. Therapeutic cancer vaccines: are we there yet?. Immunol. Rev. 2011, 239:27-44.
49. Liu J.P., et al. Telomerase in cancer immunotherapy. Biochim. Biophys. Acta 2010, 1805:35-42.
50. Vonderheide R.H., et al. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999, 10:673-679.
51. Schmidt J., et al. Telomerase-specific T-cells kill pancreatic tumor cells in vitro and in vivo. Cancer 2006, 106:759-764.
52. Nair S.K., et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat. Med. 2000, 6:1011-1017.
53. Peruzzi D., et al. A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma. Mol. Ther. 2010, 18:1559-1567.
54. Brunsvig P.F., et al. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin. Cancer Res. 2011, 17:6847-6857.
55. Mavroudis D., et al. A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies. Oncology 2006, 70:306-314.
56. Su Z., et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J. Immunol. 2005, 174:3798-3807.
57. Suso E.M., et al. hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. Cancer Immunol. Immunother. 2011, 60:809-818.
58. Domchek S.M., et al. Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res. 2007, 67:10546-10555.
59. Vetsika E.K., et al. Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001. Cancer Immunol. Immunother. 2012, 61:157-168.
60. Greten T.F., et al. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer 2010, 10:209.
61. Schlapbach C., et al. Telomerase-specific GV1001 peptide vaccination fails to induce objective tumor response in patients with cutaneous T cell lymphoma. J. Dermatol. Sci. 2011, 62:75-83.
62. Sheridan C. Gene therapy finds its niche. Nat. Biotechnol. 2011, 29:121-128.
63. Ortiz R., et al. New gene therapy strategies for cancer treatment: a review of recent patents. Recent Pat. Anticancer Drug Discov. 2012, 7:297-312.
64. Duarte S., et al. Suicide gene therapy in cancer: where do we stand now?. Cancer Lett. 2012, 324:160-170.
65. Petrocca F., Lieberman J. Promise and challenge of RNA interference-based therapy for cancer. J. Clin. Oncol. 2011, 29:747-754.
66. Dikmen Z.G., et al. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res. 2005, 65:7866-7873.
67. Shammas M.A., et al. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia 2008, 22:1410-1418.
68. Zhang Z., et al. Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clin. Cancer Res. 2006, 12:4933-4939.
69. Saretzki G., et al. Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells. Cancer Gene Ther. 2001, 8:827-834.
70. Hochreiter A.E., et al. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clin. Cancer Res. 2006, 12:3184-3192.
71. Herbert B.S., et al. Lipid modification of GRN163, an N3'→P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 2005, 24:5262-5268.
72. Joseph I., et al. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. Cancer Res. 2010, 70:9494-9504.
73. Marian C.O., et al. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin. Cancer Res. 2010, 16:154-163.
74. Schepelmann S., et al. Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2. Cancer Res. 2007, 67:4949-4955.
75. Yu S.T., et al. Noninvasive and real-time monitoring of the therapeutic response of tumors in vivo with an optimized hTERT promoter. Cancer 2012, 118:1884-1893.
76. Kojima T., et al. In vivo biological purging for lymph node metastasis of human colorectal cancer by telomerase-specific oncolytic virotherapy. Ann. Surg. 2010, 251:1079-1086.
77. Huang P., et al. Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model. Cancer Gene Ther. 2008, 15:315-322.
78. Nemunaitis J., et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol. Ther. 2010, 18:429-434.
79. Fujiwara T., et al. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter. Curr. Cancer Drug Targets 2007, 7:191-201.
80. Brower V. Telomerase-based therapies emerging slowly. J. Natl. Cancer Inst. 2010, 102:520-521.
81. Folini M., et al. Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells. Eur. J. Cancer 2005, 41:624-634.
82. Shen Y., et al. hTERT-targeted RNA interference inhibits tumorigenicity and motility of HCT116 cells. Cancer Biol. Ther. 2008, 7:228-236.
83. Hemann M.T., et al. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 2001, 107:67-77.
84. Fu X.H., et al. Combination of telomerase antisense oligonucleotides simultaneously targeting hTR and hTERT produces synergism of inhibition of telomerase activity and growth in human colon cancer cell line. World J. Gastroenterol. 2005, 11:785-790.
85. Xia W., et al. Bioreducible polyethylenimine-delivered siRNA targeting human telomerase reverse transcriptase inhibits HepG2 cell growth in vitro and in vivo. J. Control. Release 2012, 157:427-436.
86. Tamakawa R.A., et al. Telomerase inhibition potentiates the effects of genotoxic agents in breast and colorectal cancer cells in a cell cycle-specific manner. Cancer Res. 2010, 70:8684-8694.
87. Fujiwara T., et al. Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy. Int. J. Cancer 2006, 119:432-440.
88. Dong X., et al. siRNA inhibition of telomerase enhances the anti-cancer effect of doxorubicin in breast cancer cells. BMC Cancer 2009, 9:133.
89. Goldblatt E.M., et al. The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel. Mol. Cancer Ther. 2009, 8:2027-2035.
90. Goldblatt E.M., et al. Lipid-conjugated telomerase template antagonists sensitize resistant HER2-positive breast cancer cells to trastuzumab. Breast Cancer Res. Treat. 2009, 118:21-32.
91. Mizukoshi E., et al. Comparative analysis of various tumor-associated antigen-specific T-cell responses in patients with hepatocellular carcinoma. Hepatology 2011, 53:1206-1216.
92. Agarwal M., et al. Inhibition of telomerase activity enhances hyperthermia-mediated radiosensitization. Cancer Res. 2008, 68:3370-3378.
93. Hacein-Bey-Abina S., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302:415-419.
94. Blasco M.A. Telomere length, stem cells and aging. Nat. Chem. Biol. 2007, 3:640-649.
95. Buttiglieri S., et al. The aging effect of chemotherapy on cultured human mesenchymal stem cells. Exp. Hematol. 2011, 39:1171-1181.